Search Results

Madrigal Pharmaceuticals, Inc. today announced that Carole Huntsman has been appointed Chief Commercial Officer.

Huntsman Cancer Institute at the University of Utah, a pioneering innovator dedicated to developing more effective ways to care for and prevent cancer, announced plans for a new Huntsman Cancer Institute comprehensive cancer center in Utah County.

United Imaging, a global leader in advanced medical imaging and radiotherapy equipment, announced that The Center for Quantitative Cancer Imaging at Huntsman Cancer Institute, part of the University of Utah health care system in Salt Lake City, has installed another United Imaging PET/CT scanner.

Vivos Therapeutics, Inc. (the “Company” or “Vivos”) (NASDAQ:VVOS) today announced that Kirk Huntsman, Vivos’ Chairman and Chief Executive Officer, will be presenting at the Emerging Growth Conference at 12:35 pm ET on Wednesday, February 22, 2023.

United Imaging, a global leader in advanced medical imaging and radiotherapy equipment, announced that The Center for Quantitative Cancer Imaging at Huntsman Cancer Institute, part of the University of Utah health care system in Salt Lake City, has installed its first of two United Imaging PET/CT scanners, which brings state-of-the-art molecular imaging technology to the CQCI clinical research lab.

Mevion Medical Systems announced that the first proton center in the Mountain West, the Senator Orrin G. Hatch Center for Proton Therapy, has opened at Huntsman Cancer Institute at the University of Utah and began treating patients on May 11th with the MEVION S250i Proton Therapy System®.

Madrigal Pharmaceuticals, Inc. announced that the company granted equity awards to Carole Huntsman, the Company’s new Chief Commercial Officer and Senior Vice President and twelve other new employees, in each case with a grant date of November 20, 2023, as equity inducement awards under the terms of the company’s 2023 Inducement Plan.

Kazia Therapeutics Limited (NASDAQ: KZIA; ASX: KZA), an oncology-focused drug development company, is pleased to announce the publication in Molecular Cancer Therapeutics highlighting paxalisib preclinical data stemming from the research collaboration with the Huntsman Cancer Institute at the University of Utah in Salt Lake City, UT.

Through its collaborative network focused on expanding the application of precision medicine in oncology, Caris will support Huntsman Cancer Institute’s work to understand cancer from its beginnings and use that knowledge to improve cancer treatments